Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLSAI.L Regulatory News (LSAI)

  • There is currently no data for LSAI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Issue of shares to directors in lieu of fees & TVR

30 Oct 2020 07:00

RNS Number : 6769D
Location Sciences Group PLC
30 October 2020
 

30 October 2020

 

Location Sciences Group PLC

("Location Sciences" or the "Company")

 

Issue of shares to directors in lieu of fees and

change to Total Voting Rights

 

Location Sciences Group PLC, (AIM: LSAI), the leading location verification company, announces the issue of a total of 16,969,098 new ordinary shares of 0.1p each in the Company ("New Ordinary Shares") to a number of directors as payment for fees owed for certain periods since 1 February 2020 totalling £81,451.67 further details of which are set out below. The New Ordinary Shares are being issued at a price of 0.48p per share, a 6.7 per cent. premium to the closing mid-market share price on 29 October 2020.

As previously announced, following the onset of Covid-19, the Board took swift cost reduction measures to mitigate the impact of the downturn in revenues. These included reductions in cash fees payable to certain non-executive directors for the period from 1 February 2020 until the end of December 2020 totalling approximately £35,789. These directors have now agreed to take payment of these cash fees via the issue of 7,456,202 New Ordinary Shares. In addition, the appointment terms of certain non-executive directors include the ability for the Company to issue ordinary shares to these directors for their services in lieu of cash fees payable. The Company has therefore decided to pay these non-executive directors via the issue of 9,512,896 New Ordinary Shares for the period from 1 May 2020 until the end of December 2020 with a value as at the date of issue of approximately £45,661.

 

Given the current highly uncertain economic climate and the Company's limited cash resources, settling these accrued director fees in ordinary shares is considered appropriate and in the interests of the Company and its shareholders.

 

The New Ordinary Shares being issued to the directors of the Company and their resulting interests in the Company's ordinary shares are set out below:

 

Director

Role

No. of New Ordinary Shares issued

Interest in Ordinary Shares upon Admission

Percentage of issued share capital upon Admission

Kelvin Harrison

Non-executive Chairman

2,343,750

3,010,416

0.51%

Benjamin Chilcott

Non-executive director

2,291,667

2,291,667

0.39%

Niall Hogan

Non-executive director

5,000,000

6,263,158

1.07%

Donnie Williams

Non-executive director

7,333,681

8,277,078

1.41%

 

 

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 4 November 2020 ("Admission"). The New Ordinary Shares will represent approximately 2.89% of the Company's issued ordinary share capital following their issue and will rank pari passu in all respects with the Company's existing ordinary shares.

 

Total Voting Rights

 

Upon Admission, the issued share capital of the Company will consist of 587,337,398 ordinary shares of 0.1p each. The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company from Admission will be 587,337,398. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Further details and the information required in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014 are set out at the end of this announcement.

 

For further information please contact:

 

Location Sciences Group PLC

via Milk & Honey PR

Mark Slade, Chief Executive Officer

 

David Rae, CFO and Commercial Director

 

 

 

Allenby Capital (Nominated Adviser)

Tel: +44 (0)20 3328 5656

David Hart

James Hornigold

 

 

Peterhouse Capital (Broker)

Charles Goodfellow

Eran Zucker

Tel: +44 (0) 20 7220 9791

 

Milk & Honey PR

Tel: +44 (0)20 3637 7310

Kirsty Leighton

 

Jessica Ballinger

 

 

 

About Location Sciences Group PLC:

 

Location Sciences is the pre-eminent global location verification provider to the $160 billion digital advertising industry. Working in partnership with brands, media agencies and suppliers to reduce ad-wastage and improve the effectiveness of location-based advertising campaigns.

 

The digital advertising market-place remains unregulated and un-monitored, with an estimated $19 billion wasted on ad-fraud in 2018. Location Sciences has developed Verify, the world's first independent location verification product. Utilising sophisticated machine learning and pattern recognition technologies, Verify detects location ad-fraud and shines a light on location data inaccuracy with the aim of bringing back integrity, transparency and trust to the market place.

 

Rule 26 website: www.locationsciencesgroup.ai

Verify website: www.locationsciences.ai

LinkedIn: https://www.linkedin.com/company/locationsciences

Twitter: @LocationSci

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

PDMRs:

Kelvin Harrison

Non-executive Chairman

Benjamin Chilcott

Non-executive director

Niall Hogan

Non-executive director

Donnie Williams

Non-executive director

 

 

2

Reason for the notification

a)

Position/status

See 1a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Location Sciences Group PLC

b)

LEI

213800MKYV25HW2IAX70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

ordinary shares of 0.1p 

GB00BGT36S19

b)

Nature of the transaction

Issue of ordinary shares in consideration of payment of fees

c)

Price(s) and volume(s)

Price: 0.48p

 

Volumes:

 

Kelvin Harrison

2,343,750

Benjamin Chilcott

2,291,667

Niall Hogan

5,000,000

Donnie Williams

7,333,681

 

 

 

 

d)

Aggregated information

- Aggregated volume

- Price

n/a

 

e)

Date of the transaction

30 October 2020

f)

Place of the transaction

Outside of a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCKZMZGVLNGGZM
Date   Source Headline
18th Sep 20177:00 amRNSHalf-year Report and Trading Update
14th Sep 20176:03 pmRNSTR-1: Notification of major holdings
13th Sep 201712:40 pmRNSTR-1: Notification of major holdings
11th Sep 20177:00 amRNSLaunch of Location Sciences
6th Sep 20174:59 pmRNSTR-1: Notification of major holdings
5th Sep 20172:49 pmRNSTR-1: Notification of major holdings
29th Aug 20177:00 amRNSNew Directorship
25th Aug 20171:31 pmRNSTR-1: Notification of major holdings
24th Aug 20171:17 pmRNSTR-1: Notification of major holdings
10th Aug 20177:00 amRNSSettlement of credit facility and loan note
9th Aug 20173:00 pmRNSTR-1: Notification of major holdings
28th Jul 20173:43 pmRNSTR-1: Notification of major holdings
27th Jul 20174:04 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
24th Jul 201711:54 amRNSResult of AGM and GM
24th Jul 20177:01 amRNSAGM Statement
24th Jul 20177:00 amRNSResult of Open Offer
17th Jul 20177:00 amRNSProxama signs agreement with Rail Delivery Group
13th Jul 20177:00 amRNSContract Renewal
3rd Jul 20176:01 pmRNSHolding(s) in Company
30th Jun 201711:31 amRNSResult of Placing
30th Jun 20177:01 amRNSProposed Placing
30th Jun 20177:00 amRNSFinal Results
25th May 20177:00 amRNSNew Contracts
18th May 20177:00 amRNSBoard Changes
17th May 20177:00 amRNSConclusion of the Strategic Review
27th Apr 20171:07 pmRNSNotification of Interest In Shares
28th Mar 20172:04 pmRNSIssue of Equity and Total Voting Rights
7th Mar 20177:00 amRNSDirector Declaration
1st Mar 20174:39 pmRNSResult of General Meeting
1st Mar 20177:00 amRNSNew Contract Win
16th Feb 20177:00 amRNSAppointment of Non-Executive Chairman
13th Feb 20177:00 amRNSPosting of Circular and Notice of General Meeting
9th Feb 20173:40 pmRNSHolding(s) in Company
6th Feb 20177:00 amRNSNew Contract Win
3rd Feb 20177:00 amRNSIssue of Equity
23rd Jan 20177:00 amRNSNew Partnership
10th Jan 20177:00 amRNSBeacon network expansion
5th Jan 201710:20 amRNSTotal Voting Rights
3rd Jan 20178:00 amRNSBlock listing
21st Dec 20167:00 amRNSNew Contract
13th Dec 20167:00 amRNSTrading and Funding update
25th Nov 20167:00 amRNS'Santa Forgot' campaign for Alzheimer's Research
29th Sep 20167:00 amRNSHalf-year Report
23rd Sep 20162:55 pmRNSHolding(s) in Company
22nd Sep 20165:22 pmRNSExercise of Options
22nd Sep 20167:00 amRNSNew Contract
2nd Sep 20167:00 amRNSGoogle Certification
11th Aug 20163:24 pmRNSTR-1 Notification of Major Interest in Shares
11th Aug 20163:20 pmRNSDirector/PDMR Shareholding
27th Jul 20164:01 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.